JP2010518020A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518020A5
JP2010518020A5 JP2009548460A JP2009548460A JP2010518020A5 JP 2010518020 A5 JP2010518020 A5 JP 2010518020A5 JP 2009548460 A JP2009548460 A JP 2009548460A JP 2009548460 A JP2009548460 A JP 2009548460A JP 2010518020 A5 JP2010518020 A5 JP 2010518020A5
Authority
JP
Japan
Prior art keywords
rab
doc
antigen
coh
cohesin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009548460A
Other languages
English (en)
Japanese (ja)
Other versions
JP5543785B2 (ja
JP2010518020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/052714 external-priority patent/WO2008097817A2/en
Publication of JP2010518020A publication Critical patent/JP2010518020A/ja
Publication of JP2010518020A5 publication Critical patent/JP2010518020A5/ja
Application granted granted Critical
Publication of JP5543785B2 publication Critical patent/JP5543785B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009548460A 2007-02-02 2008-01-31 ヒト化ターゲティングモノクローナル抗体と複合体を形成する複数の可変抗原 Expired - Fee Related JP5543785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88802907P 2007-02-02 2007-02-02
US60/888,029 2007-02-02
PCT/US2008/052714 WO2008097817A2 (en) 2007-02-02 2008-01-31 Multivariable antigens complexed with targeting humanized monoclonal antibody

Publications (3)

Publication Number Publication Date
JP2010518020A JP2010518020A (ja) 2010-05-27
JP2010518020A5 true JP2010518020A5 (https=) 2011-03-17
JP5543785B2 JP5543785B2 (ja) 2014-07-09

Family

ID=39682338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009548460A Expired - Fee Related JP5543785B2 (ja) 2007-02-02 2008-01-31 ヒト化ターゲティングモノクローナル抗体と複合体を形成する複数の可変抗原

Country Status (16)

Country Link
US (3) US7786267B2 (https=)
EP (2) EP2684889A3 (https=)
JP (1) JP5543785B2 (https=)
KR (1) KR20090114425A (https=)
CN (1) CN101657464A (https=)
AU (1) AU2008214077B2 (https=)
BR (1) BRPI0807344A2 (https=)
CA (1) CA2715042C (https=)
DK (1) DK2114985T3 (https=)
ES (1) ES2536900T3 (https=)
IL (1) IL200092A0 (https=)
MX (1) MX2009008143A (https=)
NZ (2) NZ578657A (https=)
TW (1) TW200846371A (https=)
WO (1) WO2008097817A2 (https=)
ZA (1) ZA200905447B (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786267B2 (en) * 2007-02-02 2010-08-31 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
KR20090114430A (ko) * 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
US20080254047A1 (en) * 2007-02-23 2008-10-16 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through CLEC-6
MX2009008926A (es) * 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
AU2010222928B2 (en) * 2008-07-16 2012-11-29 Baylor Research Institute Antigen presenting cell targeted vaccines
EP2307443B1 (en) * 2008-08-07 2013-10-02 Yeda Research And Development Company Ltd. Affinity purification by cohesin-dockerin interaction
EP2406289B1 (en) 2009-03-10 2017-02-22 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
DK2406286T3 (en) 2009-03-10 2016-08-22 Baylor Res Inst Anti-cd40 antibodies and uses thereof
US9097713B2 (en) * 2009-09-02 2015-08-04 The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
JP2013504599A (ja) * 2009-09-14 2013-02-07 ベイラー リサーチ インスティテュート ランゲルハンス細胞に向けられたワクチン
MX2012012833A (es) * 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20120128710A1 (en) * 2010-11-02 2012-05-24 Baylor Research Institute Enhancement of Pathogen-Specific Memory Th17 Cell Responses
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
AR088428A1 (es) * 2011-08-25 2014-06-11 Baylor Res Inst Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos
WO2013033104A1 (en) * 2011-08-29 2013-03-07 Baylor Research Institute CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR DECTIN-1 AND TOLL-LIKE RECEPTOR 2 (TLR2)
KR102274211B1 (ko) * 2011-11-23 2021-07-09 인3바이오 리미티드 재조합 단백질 및 그들의 치료적 용도
EP2859018B1 (en) * 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
CN103044552B (zh) * 2012-12-11 2019-01-29 中国医学科学院病原生物学研究所 人源化的抗树突状细胞表面dec-205分子的单克隆抗体
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
MX2017010072A (es) * 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3424538A1 (en) * 2017-07-06 2019-01-09 Centre National De La Recherche Scientifique Bioconjugates with a controlled degree of conjugation, their process of preparation, and the reagents for their preparation
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
IL263409B2 (en) 2018-12-02 2023-06-01 Linet Spol Sro Detection of tiny movement in the human body
EP3947454A1 (en) 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
CN110790836A (zh) * 2019-11-22 2020-02-14 郑州安图生物工程股份有限公司 一种人抑制素b的单克隆抗体及其应用和试剂盒
JP2023525140A (ja) 2020-05-13 2023-06-14 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｏｘ４０活性化特性を有する組換えタンパク質
WO2021239838A2 (en) 2020-05-26 2021-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
CA3200878A1 (en) 2020-11-12 2022-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
EP4267176A1 (en) 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
CA3209251A1 (en) 2021-01-29 2022-08-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
KR20240103030A (ko) 2021-11-17 2024-07-03 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 범용 사르베코바이러스 백신
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) * 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) * 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
CA2231582A1 (en) 1995-10-17 1997-04-24 Genencor International, Inc. Enzymatic array and process of making same
FR2748479A1 (fr) * 1996-05-10 1997-11-14 Pasteur Institut Polypeptide comportant un nouveau domaine cohesine de type ii, composition enzymatique en comportant et fragments d'adn codant pour ces polypeptides
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
JP2000157282A (ja) * 1998-11-30 2000-06-13 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
WO2000056901A2 (en) * 1999-03-24 2000-09-28 Board Of Regents, The University Of Texas System Linear and circular expression elements
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
IL152748A0 (en) * 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
AU2002332598A1 (en) * 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
US20050106700A1 (en) * 2001-10-11 2005-05-19 Tsuyoshi Nomura Method of purifying recombinant fused protein and method of producing protein using the same
JP2004236504A (ja) * 2003-02-03 2004-08-26 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
US20050064509A1 (en) * 2003-09-23 2005-03-24 The Regents Of The University Of California Use of templated self assembly to create novel multifunctional species
JP2008504222A (ja) * 2003-12-15 2008-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 新規の抗ｄｃ−ｓｉｇｎ抗体
EP1874824A4 (en) * 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
US7786267B2 (en) * 2007-02-02 2010-08-31 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
KR20090114430A (ko) * 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑

Similar Documents

Publication Publication Date Title
JP2010518020A5 (https=)
CN112534052B (zh) 全新il-21前药及使用方法
JP2010517538A5 (https=)
JP2021502810A5 (https=)
Ahmed et al. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
AU2008214036B2 (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (DC- ASGPR)
US6979726B1 (en) Immunoconjugates
CN119386199A (zh) 全新被掩蔽的细胞因子及其应用
WO2019129053A1 (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
JP2010536386A5 (https=)
CN103833852A (zh) 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
RU2009123409A (ru) Новые антипролиферативные антитела
JP2007181458A (ja) 組み換え三重足場ベースポリペプチド
De Jonge et al. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3× anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model
Zekri et al. Immunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies
WO2001079494A1 (fr) Anticorps agonistes
CN118978595A (zh) 抗tim3单克隆抗体和嵌合抗原受体
Dreier et al. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities
CA2463616A1 (en) Affinity enhancement agents
US12264189B2 (en) Methods and materials for treating cancer
Saleh et al. RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma
WO2025011540A1 (zh) 一种抗体Fab片段的二聚体、其制备方法及应用
Paul et al. Tumor gene therapy by MVA-mediated expression of T-cell–stimulating antibodies
Waldmann Lymphokine receptors: a target for immunotherapy of lymphomas
JPWO2023164288A5 (https=)